Every round on record, with the sources behind each and the investors on them.
No description yet.
solsticeoncology.comBiotechFounded 2026Fewer than 25 people
3 sources
Developing: it holds up against its sources so far, and firms up as more reporting lands.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series A [ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $225M | 2026-09-09 | not stated | No recent discussion |
3 sources [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 of 3 sources | ||||
Solstice Oncology is a clinical-stage immuno-oncology company developing a treatment to attack cancer before surgery, starting with colon cancer.
Solstice is testing whether a short course of porustobart plus a PD-1 inhibitor before surgery can improve outcomes in microsatellite-stable stage II–III colon cancer, a large patient population that has historically not benefited from immunotherapy, while earlier Harbour BioMed studies reported a 30% response rate and an 8.4-month median response duration in a late-line setting. Its $225 million Series A funds a rapid Phase 2 program built around a licensed, next-generation CTLA-4 antibody and a team that had already filed and cleared an IND.
Checked against 8 sources on Oct 1
Also named as backers in company research: RAven, Harbour BioMed
| EARLIER ROUNDS FROM COMPANY RESEARCH · DEVELOPING | ||||
| Equity partnership | over $50 million of equity in Solstice | 2026-02-22 | not stated | |